BTLA activation suppresses cancer-specific CD8+ T-cell proliferation and differentiation, and its high expression in whole cancer tissue or infiltrating T cells is associated with poor outcomes in patients with epithelial ovarian, gallbladder, and gastric cancers [47,48,49,50,51,52]. This evidence concerns the gene CD8A and cancer.